Kymeris' Breakthrough Platform Against Solid Cancers
- Infiltrates and Reprograms the Tumor Microenvironment -
- Turns Cold tumors, Hot -
- Delivers Complex Molecular Therapies Inside Tumor -
UNIQUE immunoTHERAPEUTIC Eukaryotic PLATFORM Delivering multiple THERAPIES INTO TUMOR
Reprograms the Tumor Micro-environment (TME) to reverse cancer-induced local Immunosuppression
In extensive preclinical in vivo animal studies, engineered eukaryotic cells have shown outstanding efficacy in tumors from 80 to 100%. The constructs are derived from a non-pathogenic-in-Man protozoan, Neospora. .
Novel, proprietary mechanisms of action (MOA) transform the Tumor Microenvironment (TME) from immuno-suppressive to immune competent – and, by extension, tumors from COLD to HOT.
Engineered to Deliver Molecular Therapy Into Cancer across the Tumor Microenvironment Barrier
Kymeris’ platform is able to deliver multiple payloads of therapeutic interest, unimpeded by the Tumor Microenvironmental barrier, into cancer cells. Engineered derivatives delivered multiple agents within tumors, including antibodies and cytokine, or expressed other protein-based therapeutic constructs such as an antigen, and an antibody fragment.. Our strategy is to pursue both in-house products and, in co-operation with pharmaceutical / biotechnology companies, to improve delivery of their proprietary molecules for better therapeutic outcomes.
The Company
Kymeris is a pre-clinical immuno-oncology company whose novel platform technology focuses on improving solid cancer cure rates, and kinder clinical protocols. Kymeris is a founder-controlled private corporation with development activities carried out in Europe and in the United States. It now seeks its first round of exterior financing.
Characteristics
Multifunctional, Tumor-tropic Immunotherapeutic Delivery Platform
Kymeris’ platform technology enables a breakthrough multifunctional approach to treating solid cancers. Several compelling characteristics differentiate it from competing technologies. The array of Neospora’s characteristics may represent a transformative opportunity for improving outcomes in solid cancers by its unique ability to preferentially traffic into tumors, within which its engineered derivatives deliver complex, multiple payloads that it synthesizes from in-house machinery during replication.
- Preferentially localizes and penetrates the Tumor Micro-Environment (TME), the "protective ecosystem" that impedes many therapeutic agents from reaching cancer cells.
- Adaptable to deliver payloads while fully confined in the TME (minimizing potential effect on other tissues)
- Reprograms the TME from an immuno-suppressive into an immune-competent state, acting even against COLD tumors (immune-unreactive), and stimulates potent cancer-destructive Th1 immune response.
- Universal infiltrative design for "mechanistic" active penetration of the TME, and intracellular entry in almost any cancer.
- Expected high safety from a NON-PATHOGENIC-IN-MAN eukaryotic organism
How It Works
Therapeutic narrative
- By design, Kymeris’ genetically-enhanced cells localize at solid cancer sites and penetrate directly into the Tumor Micro-Environment (TME).
- Walled-in by the TME, the constructs self activate. Since major anti-cancer functionality occurs in the TME – not systemically – any possible unwanted effects elsewhere in the body are largely precluded.
- A synergy of well-characterized Mechanisms of Action (MoAs) unleashes 3 broad anti-tumor activities:
- Intratumor Secretion or Expression of Multiple, Complex Transgenic Payloads.
- First, the actively-infiltrating cellular agents penetrate the TME physical barrier, and spread in the tumor.
- Second, they transform the cancer-induced immune suppressors of the TME to restore immune competency and susceptibility in the tumor. A potent Th-1 immune response is called forth which, no longer impeded by the TME.
- Third, the constructs infiltrate cancer cells and replicate, provoking lysis, and release of neoantigens that reinforce systemic response and adaptive immunity.
Additional Advantages
Technology Plus
- Readily Modified for Delivery of Complex Molecular Therapies to TME. The cell constructs have a broad capacity to vector / deliver additional therapeutic agents. Both surface and secretory expression has been achieved. Agents have been developed in-house which successfully target antigens and / or deliver to tumor sites proteins, antigens, ligands and antibodies. In future, pharmaceutical and biotech companies may achieve for their proprietary molecules broadened application and better clinical outcomes though partnerships with us.
- Action is self-limiting in space and time. Following treatment, constructs DO NOT persist in the body. In pre-clinical studies, they were rapidly cleared from the body (a matter of hours or days in mice), leaving no residual trace other than immunological memory to neoantigens released in cancer lysis.
- Less Invasive Administration. Less-invasive routes of administration have been shown to be effective at a distance (sub-cutaneous, nasal and mucosal), in addition to standard intratumoral / peritumoral and intravenous routes.
- Features for Safety. We expect to confirm, with programmed primate studies, a very favorable safety profile. The base constructs are derived from cells considered non pathogenic in Man. As eukaryotic cellular constructs, they have no capacity to integrate the cancer genome, precluding risk of cancer mutagenesis. This order of organisms is extremely stable.
Features of Kymeris' Cellular Platform against Solid Cancers
